Drugs / TGFBR2 KO CAR27/IL-15 NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07509008 | Aug 2026 → Jul 2028 expected | gastric adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFBR2 KO CAR27/IL-15 NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509008 ↗ |
| Action | Inhibit | “TGFBR2 KO” NCT07509008 ↗ |
| Modality | Cell therapy | “allogeneic donor CAR-transduced CB-derived NK cells” NCT07509008 ↗ |
| Route | Other | “delivered intraperitoneally” NCT07509008 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT07509008 ↗ |